Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Objective: The aim of this study is to capture market dy...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1031910/full |
| _version_ | 1811293261370753024 |
|---|---|
| author | Teresa Barcina Lacosta Arnold G. Vulto Arnold G. Vulto Isabelle Huys Steven Simoens |
| author_facet | Teresa Barcina Lacosta Arnold G. Vulto Arnold G. Vulto Isabelle Huys Steven Simoens |
| author_sort | Teresa Barcina Lacosta |
| collection | DOAJ |
| description | Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Objective: The aim of this study is to capture market dynamics for tumor necrosis factor (TNF)-alpha inhibitors and competing molecules in Southern European markets (2011–2020), and to evaluate the benefits of the competition generated by the availability of biosimilars.Methods: This study is based on a literature review examining market characteristics for TNF-alfa inhibitors and competing immunomodulator molecules, and on the quantitative analysis of market data for these molecules in Italy, Portugal and Spain.Results: Following biosimilars availability in Italian, Portuguese and Spanish markets, there has been an expansion in the overall access to TNF-alfa inhibitor pharmaceuticals. Further, savings have been generated within the TNF-alfa inhibitors class even after the increased use of these molecules. However, the potential of infliximab, etanercept and adalimumab biosimilars to generate price competition outside of their own drug class appeared limited in the studied markets. Considering this limitation and that shifts towards on-patent and higher-cost therapies have occurred after TNF-alfa inhibitor biosimilars availability, the importance of investing in biosimilars development for still on-patent immunology biologics is emphasized.Conclusion: This study highlights the need for policies that do not only seek higher utilization of biosimilars, but that also support a sustainable market for these products. This is expected to foster the future development of biosimilar medicines. |
| first_indexed | 2024-04-13T04:58:42Z |
| format | Article |
| id | doaj.art-52c5da5bb0a5423aa8dd726a416a8179 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T04:58:42Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-52c5da5bb0a5423aa8dd726a416a81792022-12-22T03:01:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-12-011310.3389/fphar.2022.10319101031910Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysisTeresa Barcina Lacosta0Arnold G. Vulto1Arnold G. Vulto2Isabelle Huys3Steven Simoens4Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumHospital Pharmacy, Erasmus University Medical Center, Rotterdam, NetherlandsDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumBackground: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Objective: The aim of this study is to capture market dynamics for tumor necrosis factor (TNF)-alpha inhibitors and competing molecules in Southern European markets (2011–2020), and to evaluate the benefits of the competition generated by the availability of biosimilars.Methods: This study is based on a literature review examining market characteristics for TNF-alfa inhibitors and competing immunomodulator molecules, and on the quantitative analysis of market data for these molecules in Italy, Portugal and Spain.Results: Following biosimilars availability in Italian, Portuguese and Spanish markets, there has been an expansion in the overall access to TNF-alfa inhibitor pharmaceuticals. Further, savings have been generated within the TNF-alfa inhibitors class even after the increased use of these molecules. However, the potential of infliximab, etanercept and adalimumab biosimilars to generate price competition outside of their own drug class appeared limited in the studied markets. Considering this limitation and that shifts towards on-patent and higher-cost therapies have occurred after TNF-alfa inhibitor biosimilars availability, the importance of investing in biosimilars development for still on-patent immunology biologics is emphasized.Conclusion: This study highlights the need for policies that do not only seek higher utilization of biosimilars, but that also support a sustainable market for these products. This is expected to foster the future development of biosimilar medicines.https://www.frontiersin.org/articles/10.3389/fphar.2022.1031910/fullbiosimilarsbiological medicinal productsoff-patent biologicalsSouthern-EuropeTNF-alfa inhibitorsprice competition |
| spellingShingle | Teresa Barcina Lacosta Arnold G. Vulto Arnold G. Vulto Isabelle Huys Steven Simoens Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis Frontiers in Pharmacology biosimilars biological medicinal products off-patent biologicals Southern-Europe TNF-alfa inhibitors price competition |
| title | Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis |
| title_full | Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis |
| title_fullStr | Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis |
| title_full_unstemmed | Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis |
| title_short | Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis |
| title_sort | evaluating the benefits of tnf alfa inhibitor biosimilar competition on off patent and on patent drug markets a southern european analysis |
| topic | biosimilars biological medicinal products off-patent biologicals Southern-Europe TNF-alfa inhibitors price competition |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1031910/full |
| work_keys_str_mv | AT teresabarcinalacosta evaluatingthebenefitsoftnfalfainhibitorbiosimilarcompetitiononoffpatentandonpatentdrugmarketsasoutherneuropeananalysis AT arnoldgvulto evaluatingthebenefitsoftnfalfainhibitorbiosimilarcompetitiononoffpatentandonpatentdrugmarketsasoutherneuropeananalysis AT arnoldgvulto evaluatingthebenefitsoftnfalfainhibitorbiosimilarcompetitiononoffpatentandonpatentdrugmarketsasoutherneuropeananalysis AT isabellehuys evaluatingthebenefitsoftnfalfainhibitorbiosimilarcompetitiononoffpatentandonpatentdrugmarketsasoutherneuropeananalysis AT stevensimoens evaluatingthebenefitsoftnfalfainhibitorbiosimilarcompetitiononoffpatentandonpatentdrugmarketsasoutherneuropeananalysis |